MBS-303 - Drug Targets, Indications, Patents - Synapse - Patsnap

mbs303MBS-303: a CD20 inhibitors, CD3 stimulants Drug, Initially developed by Beijing Mabworks Biotech Co., Ltd.,MBS303, composed of a 2:1 bispecific antibody structure, binds to CD20 with two arms and CD3 molecule with one arm to increase affinity with tumor cells and decrease the off-target toxicity